Maureen E. Trudeau, MD | Authors

Optimizing Adjuvant Breast Cancer Chemotherapy: Rationale for the MA.21 Study

May 01, 2001

Recently initiated is a phase III randomized trial (MA.21 trial) of adjuvant chemotherapy for node-positive and high-risk node-negative, premenopausal and postmenopausal (£ 60 years) women with breast cancer who have